PubMed Health⌕ Search

Biomedical subjects

G Citro

Publications and source records attributed to G Citro.

81 records · Page 5Linked to original sources
PubMedDate not supplied

[Importance of the determination of fructosamine in monitoring diabetic patients].

Protein glycosylation plays a role in the metabolic control and in the pathogenesis of diabetic complications; indeed it has an important role in the process leading to micro- and macroangiography in diabetes. In an attempt to determine the clinical value of fructosamine assay for monitoring type II diabetic patients, the correlation of fructosamine and HbA1c, glycemia, cholesterol and triglycerides was studied. The results show that fructosamine is a good index for short-term metabolic control of diabetic patients.

Blood Glucose↗
PubMedDate not supplied

[Clinical use of growth hormone and clonidine in growth disorders].

The aim of this study was to investigate the effects of the recombinant human growth hormone and of the alpha-2 adrenergic agonist clonidine in three groups of prepuberal children with growth disorders. Three children with GH-deficiency were treated with 0.5 U kg/week i.m. of recombinant growth hormone; 13 children (7 with constitutional delay of growth and 6 with familiar short stature) were treated with 0.08 mg/m2/die per os of clonidine. The results confirmed the growth promoting effect of GH in GH-deficiency. Clonidine restored GH-secretion in children with constitutional delay, but had a very poor or no effect in familiar short children.

Adolescent↗
PubMedDate not supplied

Immunochemical determination of lonidamine in rat tissues and blood serum.

Lonidamine (LND) is an antitumor drug which interferes selectively with the energy metabolism of neoplastic cell. Because of its physico-chemical properties, LND determination with conventional methods, i.e. high performance liquid chromatography and spectrofluorimetry, gives rise to several problems: LND is a lipotropic drug which becomes intimately associated with biological membranes so that it is impossible to extract all the drug bound, thus leading to an underestimation of the LND content in cells and tissues. These difficulties can be overcome by the immunoenzymatic method described here. The assay is simple, rapid, practical, highly sensitive (2-5 ng/ml) and particularly suitable for the analysis of multiple samples (twelve samples in triplicate for each plate). There is, moreover, a great improvement in data reproducibility.

Animals↗
PubMedDate not supplied

Quantitation of adriamycin content by a sensitive immunochemical assay.

An immunoenzymatic method for the quantitation of adriamycin (ADM) content in tissues as well as in tumor cells has been developed. This procedure has three main advantages. Firstly, it is possible to carry out the determination on whole homogenates and blood serum, thus avoiding the extractive procedures. Secondly, very low ADM concentrations (0.2 ng) can be detected. Thirdly, it is possible to determine simultaneously and in triplicate both the standard curve and ADM concentration in twelve different samples with a great reduction of the experimental variability.

Animals↗
PubMedDate not supplied

Adriamycin resistance modulation induced by lonidamine in human breast cancer cells.

The effect of Lonidamine (LND), an energolytic chemosensitizing agent, on the MDR (multidrug resistant) phenotype of a human breast cancer cell line (MCF-7) has been studied. The intracellular adriamycin (ADR) accumulation and distribution, the plasma membrane potential and the P170 glycoprotein phosphorylation, have been analysed after LND treatment. The analysis of the subcellular localisation of ADR in both wild type and resistant MCF-7 cells treated with ADR or ADR + LND revealed that LND induced an ADR intracellular redistribution in both cell lines. MCF-7 ADR resistant cells exposed to LND (50 micrograms/ml) showed a change in the electrical charges distribution across the plasma membrane and a time-dependent reduction of P170 phosphorylation (70% at 24 hr). These effects were associated with a marked increase in intracellular ADR accumulation in resistant cells.

ATP Binding Cassette Transporter, Subfamily B, Mem↗
PubMedDate not supplied

Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.

Several polycations such as polylysine polymers are efficient transfection agents due to their capacity to bind DNA at physiological pH. By linking a ligand for a cell surface receptor to the polycation domain, a selective delivery of polyanionic compounds such as oligodeoxynucleotides (ODNs) without cell membrane-disruption can be achieved. Therefore, we aimed to develop this strategy to improve the uptake of oligomers in cancer cells. In particular, cationic polymers polylysine were covalently linked to a molecule of Folic Acid (FA) to deliver complexed ODNs in human melanoma (M-14) cells which express FA receptors. Since in these cells c-myc oncogene seems to play a crucial role in tumor growth, we used a c-myc antisense ODNs (15mer base antisense c-myc ODNs phosphorothioate) to inhibit its expression. The cellular uptake of the complexed ODNs was improved compared to the cellular uptake of free ODNs with a significant decrease in the intracellular c-myc protein level, resulting in a reduction of the growth rate and colony-forming capacity of the cells. No such effect was observed when ODNs in scrambled sequences were administered under the same experimental conditions. The efficacy of the uptake of the complex is receptor-related since a Transferrin-polylysine carrier produced no significant biological effects (in melanoma cells the Fe uptake is mediated by an oxidoreductase present in the cell membrane and not by Transferrin receptor pathway). Our results demonstrate that: a) By choosing the appropriate ligand for the membrane receptor present on the target cells, selective targeting of ODNs can be achieved. b) The uptake of the ODNs can be improved by receptor-mediated endocytosis. c) In a model system the complexed ODNs are capable of impairing gene product synthesis and function.

Drug Carriers↗